Loading page...
Loading page...
Europe's healthtech sector sits at the intersection of world-class clinical research, universal healthcare systems, and a regulatory environment that — while demanding — provides a credibility moat once navigated.
Europe's healthtech sector sits at the intersection of world-class clinical research, universal healthcare systems, and a regulatory environment that — while demanding — provides a credibility moat once navigated. Over 3,500 digital health startups operate across the EU, raising EUR 5.2 billion in venture capital in 2024, with Germany, France, and the Nordics accounting for the majority of deal flow.
The EU's Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR), fully applicable since 2021 and 2022 respectively, raised the bar for market entry but also cleared the field of low-quality competitors. Software-as-a-Medical-Device (SaMD) classification has become a strategic differentiator: startups like Ada Health, Kaia Health, and Doctolib have turned regulatory compliance into a competitive advantage for hospital procurement and reimbursement negotiations.
The European Health Data Space (EHDS) regulation, formally adopted in early 2025 (Regulation (EU) 2025/327, in force since March 2025), will create the world's largest cross-border health-data infrastructure, enabling secondary use of anonymised patient data for AI training and research. For healthtech founders, this unlocks datasets at a scale that rivals US and Chinese equivalents while maintaining GDPR-grade privacy protections. Combined with EUR 8.2 billion allocated to Cluster 1 (Health) under Horizon Europe, the EU is arguably the best-funded public health innovation ecosystem globally.
The EU spends over EUR 1.4 trillion annually on healthcare (roughly 10 % of GDP), yet digital health penetration remains below 15 % in most member states, creating enormous greenfield opportunity. Germany's DiGA (Digital Health Applications) pathway has become a global model for prescription-app reimbursement, and France's Espace Numerique de Sante is onboarding 67 million citizens onto a unified digital health record.
13 EU calls mentioning Digital Health are open or opening soon. The ones closing first:

Grant below €2.5M + up to €10M equity
Grant funds up to 70% of eligible innovation costs. Investment requires due diligence.
HealthTech is consistently the #1 vertical by EIC Accelerator awards. Medical devices, diagnostics, and digital therapeutics with CE marking or MDR classification are prioritised.

Up to €4M
Grant for early-stage breakthrough technology research. 2027 dates are from the draft EIC Work Programme 2027 and are provisional until the official call is published.
Funds early-stage health R&D: organ-on-chip, AI-driven drug repurposing, novel biosensors, and brain-computer interfaces at TRL 1-4.

Up to €2.5M
Grant to develop results from an eligible research project.
Bridges the gap between Pathfinder research results and market-ready healthtech products, funding validation, prototyping, and regulatory preparation.

Topic-specific project grants
Industry, digital and space topics set their own project budgets and funding rates.
Cluster 1 (Health) is the largest single cluster with calls covering personalised medicine, infectious disease preparedness, and health system digitalisation.
Since 2018, 2,267 organisations received €1.4bn across 341 EU research and innovation projects in Digital Health, including 506 SMEs. Amounts are each organisation's own share on these projects.
Specialists: at least a third of their EU projects are in this field.
119 Digital Health projects started in the last three years. The latest:
UNICORNPiloting Integrated Non-Technological Readiness for Academic Health Startups
Led by Pno Innovation SL · Spain · 2026 · Official record ↗
SAFE-MOVESAFE-MOVE: SAFE AND ACCESSIBLE FUTURES FOR EVERYONE MOVING USING ACTIVE AND MICROMOBILITY
Led by Technische Universiteit Delft · Netherlands · 2026 · Official record ↗
6G-CARE6G-enabled Connected and Autonomous Response for eHealth
Led by Luxembourg Institute of Science and Technology · Luxembourg · 2026 · Official record ↗
DEEP-HEALTHSTRENGTHENING RESEARCH EXCELLENCE AND INNOVATION IN DIGITAL HEALTH ACROSS WIDENING EUROPE
Led by Ethnicon Metsovion Polytechnion · Greece · 2026 · Official record ↗
NIGHTNon-invasive Glucose Health Technology
Led by DiaMonTech AG · Germany · 2026 · Official record ↗
LUMINALUng Modeling and INtelligence for Advanced care: A Digital Twin Approach to Lung Cancer Diagnosis and Treatment
Led by Aalborg Universitet · Denmark · 2026 · Official record ↗
RT_NSContactFMDReal-Time Non-smooth Contact for Flexible Multibody Dynamics from Surgery to Offshore applications
Led by Imperial College of Science Technology and Medicine · United Kingdom · 2026 · Official record ↗
CONNECT4HEALTHCONNECT4HEALTH: Coordinated NCD Care Transformation through Community and Networked Health Platforms in Indonesia, Nepal, Uganda, and Ethiopia
Led by The University of Manchester · United Kingdom · 2026 · Official record ↗
DiGA pathway pioneered here; Ada Health, Doctolib DE, and Merantix's health AI division operate alongside Charite — Europe's largest university hospital.
Doctolib (valued at EUR 5.8B), Owkin, and Lifen lead a 500+ startup cluster backed by Bpifrance's health innovation programmes.
Medicon Valley spans Copenhagen-Malmo with Novo Nordisk, Lundbeck, and 300+ life-science startups; Denmark's national health data registries date back 40 years.
ISGlobal, Hospital Clinic, and the Barcelona Supercomputing Center anchor health AI research; Top Doctors and Mediktor are homegrown scale-ups.
All software classified as a medical device — including AI-powered diagnostics and clinical decision support — must undergo conformity assessment via a Notified Body. Timeline to certification averages 12-18 months.
Companion diagnostics and lab-developed tests face reclassification into higher risk categories, requiring clinical evidence and post-market surveillance.
Establishes mandatory interoperability standards (HL7 FHIR) for EHR systems and creates a legal basis for secondary use of health data for research and AI training, with strict pseudonymisation requirements.
Health data is a 'special category' under Article 9, requiring explicit consent or specific derogations for processing. Cross-border transfers of health data face additional Schrems II adequacy requirements.

Next generation scientists studying extracellular RNA
Switzerland
GemciTest: An innovative In Vitro Diagnostic for the decision-making process of pancreatic cancer treatment
France

First time ultra-sensitive and simultaneous quantification of proteins, interactions
Germany
AI-based clinical software for fully automated Cardiac Magnetic Resonance reporting
Portugal
New era of guided lens implantation in cataract surgery
Germany
Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Germany
Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
Netherlands
Transforming Molecular Diagnostics through NanoTechnology
Ireland
Enabling the next generation in search of blood cancer cures
Spain

Breaking boundaries in cancer by targeting its microenvironment
France
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
United Kingdom
First In class oliGo THerapy for Myotonic Dystrophy type 1 (DM1)
Spain

Rebuilding Joint Surface to Prevent Pain and Immobility
Finland

Empowering Libraries to Lead Co-Creation and Innovation through the European Collaborative Cloud for Cultural Heritage
Greece
PAH-ADVANCE: Accelerating the Clinical Path of NTP42
Ireland
EuRopEAn incubator for trusted and secure data value CHains
France
Direct Selective Laser Trabeculoplasty (DSLT): Accessible glaucoma care in seconds
Israel
Sustainable platform for producing new generation biotherapeutics
Belgium
Biogenic Organotropic Wetsuits
Czech Republic
Development of a platform for a new model of interaction between geneticists and patients with Mendelian diseases.
Italy

Advanced Research on Viroid Pathogenesis and Control for Agricultural Sustainability
Switzerland

An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
United Kingdom
COnstruction-phase diGItal Twin mOdel
Austria
Research on Extended And Layered Multimodalities
Spain
COMPUTER-AIDED EFFECTIVE FRACTURE RISK STRATIFICATION OF PATIENTS WITH VERTEBRAL METASTASES FOR PERSONALISED TREATMENT THROUGH ROBUST COMPUTATIONAL MODELS VALIDATED IN CLINICAL SETTINGS
Hungary
in silico bio-evolutio - novel AI paradigm for molecular biology
Poland

Development of a natural therapeutic treatment for late-stage lung cancer patients
Ireland

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
France
Accessible MRI
France
Enabling digital technologies for Holistic Health-lifestyle motivational and assisTed supeRvision supported by Artificial Intelligence Networks
Spain
Innovative solutions for colorectal surgery to prevent clinical leakage
Israel

Quantifying Atrial Fibrillation Burden to inform Screening, Treatment, and hEalth Policy
Germany
FLIARA: Female-Led Innovation in Agriculture and Rural Areas
Spain

Training the next generation of scientists on cell surface Glycans from Gram-negative gut microbiota as molecular keys to decOde the gut-immune-brain Axis
Belgium
Enabling patient specific medicines using 3D printing in hospitals and pharmacies
Finland
Impact of exposome on the course of lung diseases
Switzerland

Plant based biomanufacturing platform for immunotherapies
Italy
Sonication and Microwave Processing of Material Feedstock
Germany
Towards a harmonised pan-European monitoring of soil health descriptors
France

The first non-surgical repair for Pelvic Organ Prolapse
Israel
Hydrogen for Robust Off-road Application Modules
Germany
Disclosing the Environmentally Sensitive brain Through Interdisciplinary training in NeuroscIence and neuropSychology
Germany
EDGE MULTI SENSING FOR MEDICAL AND PHARMA APPLICATIONS
Israel
Next-generation surgical robotics to set a new standard of care in orthopaedic surgery
France

The i-Thymus: wielding the potential of gene therapy
Netherlands
Coherent control and operation tools for RES-based energy systems
Greece

The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Finland
Expanding the European EHRxF to share and effectively use health data within the EHDS
Greece

The first universal and price-neutral insulin pen
Denmark
Revolutionizing respiratory support with next-generation gas exchange technologies
Germany
Paris, France
Fund size · €300M
Seed · Series A
London, UK
Fund size · $1.24B
Series A · Series B · Growth
London, UK
Fund size · $1.3B
Series A · Series B
Rome, Italy
Fund size · €260M
Seed · Series A · Series B
Berlin, Germany
Fund size · €500M
Seed · Series A
Stockholm, Sweden
Fund size · $500M
Seed · Series A
Prague, Czechia
Fund size · €100M
Seed · Series A
Berlin, Germany
Fund size · €350M
Series A · Series B
Germany's DiGA pathway (DVG law) is the fastest route: demonstrate positive care effects in a 12-month trial, gain BfArM listing, and all 73 million statutory-insured patients can receive it on prescription. France's PECAN pathway and Belgium's mHealth validation pyramid offer alternatives. Most other EU countries lack a formal digital therapeutics reimbursement route, so hospital procurement or private insurance are the primary channels.
Class I software provides information for diagnosis support but does not directly drive clinical decisions. Class IIa software influences diagnosis or therapy — e.g., an AI that flags potential malignancies on imaging. Class IIa requires Notified Body involvement, clinical evaluation, and a quality management system (ISO 13485). Most AI-powered diagnostics fall into Class IIa or higher.
Yes, but under strict conditions. The EHDS creates 'secure processing environments' where approved researchers and companies can access pseudonymised data for secondary use. You cannot extract raw data; models must be trained inside the environment. Data access bodies in each member state will grant permits based on purpose, security measures, and ethical review.
Not directly for the EIC Accelerator (requires EU/EEA establishment). However, US companies can participate in Horizon Europe collaborative projects as associated or third-country partners. The practical route is to incorporate an EU subsidiary — Ireland, the Netherlands, and Estonia are popular choices — and apply from that entity.